ALP AI combines tonsil organoids with generative AI to quantify and reduce anti-drug antibody risk in therapeutic antibodies. We support lead optimization and asset rescue with human-relevant ADA data and sequence re-engineering. Pharma and biotech partners are invited to validate assets with us.
Products, services, technology
Covering detection to prevention of immunogenicity in preclinical biologics.
- AI-based in silico ADA scoring (license)
- Tonsil organoid ADA risk reporting per asset
- Full antibody optimization programs with milestone-linked success fees.
Cooperation possibilities
Asset ADA screening, re-engineering, and co-development partnerships.
- http://www.alpbio.ai
- Send an email
- Punit Mehra
Some insights
We help make biologic drugs safer and more reliable by reducing unexpected immune reactions. This can prevent late-stage failures, save resources, and ultimately improve access to effective treatments for patients.
We are building a human-relevant platform that addresses a real and costly problem in drug development. We combine solid science with practical application and stay honest about both the potential and the limits of our approach.
Our strengths are immunology, AI-based protein modeling, and business development in biotech. We aim to add expertise in regulatory strategy, clinical development, and scaled lab operations.
We try to make medicines less likely to cause unwanted immune reactions by testing and redesigning them before they reach patients.
Through early partnerships, access to translational funding, and connections to pharma and CRO partners for validation studies and pilot projects.
Preclinical antibody teams in biotech and pharma, CROs, immunogenicity experts, translational researchers, and investors with experience in platform biotech.
